Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-04-06
DOI
10.1111/bjh.17435
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
- (2020) Nizar J. Bahlis et al. LEUKEMIA
- Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials
- (2019) Jessica K. Roydhouse et al. JAMA Oncology
- Quality of life in multiple myeloma: considerations and recommendations
- (2019) Samantha Seitzler et al. Expert Review of Hematology
- How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
- (2019) Matthew R. LeBlanc et al. QUALITY OF LIFE RESEARCH
- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
- (2018) Xavier Leleu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study
- (2018) David Cella et al. ANNALS OF HEMATOLOGY
- High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
- (2018) Homer C. Adams et al. CYTOMETRY PART A
- General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
- (2018) S. Nolte et al. EUROPEAN JOURNAL OF CANCER
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials
- (2016) Don Robinson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
- (2016) A. Keith Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
- (2016) Marije B. Overdijk et al. JOURNAL OF IMMUNOLOGY
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
- (2015) R. Baz et al. SUPPORTIVE CARE IN CANCER
- Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
- (2013) Meletios A. Dimopoulos et al. LEUKEMIA & LYMPHOMA
- Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
- (2012) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
- (2011) Ann Kristin Kvam et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More